Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

Next Previous
Trial Profile

A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KD 018 (Primary) ; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions

Most Recent Events

  • 29 Apr 2019 Status changed from suspended to completed.
  • 28 Jul 2017 Status changed from recruiting to suspended.
  • 13 Jun 2014 Planned number of patients changed from 54 to 165, Phase changed from IB/II to II and study included an additional placebo arm. Also, primary endpoints and study inclusion/exclusion criteria have been updated accordingly.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top